» Articles » PMID: 2199532

Bone Marrow Biopsy in Monoclonal Gammopathies: Correlations Between Pathological Findings and Clinical Data. The Cooperative Group for Study and Treatment of Multiple Myeloma

Overview
Journal J Clin Pathol
Specialty Pathology
Date 1990 Jun 1
PMID 2199532
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Between January 1987 and October 1989, 561 consecutive untreated patients with monoclonal gammopathy of undetermined clinical importance (MGUS) (n = 295) or with multiple myeloma (n = 266) were evaluated in a multicentre trial. Both bone marrow biopsy and aspiration (performed at different anatomical sites) were required at presentation. Bone marrow biopsy data indicated that changes in bone marrow composition from MGUS to early multiple myeloma and to advanced multiple myeloma followed a precise pattern, including an increased percentage of bone marrow plasma cells (BMPC%), a shift from plasmocytic to plasmoblastic cytology, an increase in bone marrow cellularity and fibrosis, a change in bone marrow infiltration (becoming diffuse rather than interstitial), a decrease in residual haemopoiesis and an increase in osteoclasts. In multiple myeloma the BMPC% of biopsy specimens and aspirate were closely related, although in 5% of cases the difference between the two values was greater than 20%. Some histological features were remarkably associated with each other. For example, BMPC% was higher in cases with plasmoblastic cytology, heavy fibrosis, or reduced residual haemopoiesis. Anaemia was the clinical characteristic most influenced by bone marrow histology. The BMPC% was the only histological variable which affected the greatest number of clinical and laboratory characteristics, including, besides haemoglobin concentration, erythrocyte sedimentation rate, radiographic skeletal bone disease, and serum concentrations of monoclonal component, calcium, beta 2-microglobulin and thymidine kinase activity. These data indicate that comparative bone marrow histology in monoclonal gammopathies has clinical importance.

Citing Articles

Outcomes of primary refractory multiple myeloma and the impact of novel therapies.

Majithia N, Rajkumar S, Lacy M, Buadi F, Dispenzieri A, Gertz M Am J Hematol. 2015; 90(11):981-5.

PMID: 26214732 PMC: 5801545. DOI: 10.1002/ajh.24131.


Myelomagenesis: capturing early microenvironment changes.

Korde N, Maric I Semin Hematol. 2011; 48(1):13-21.

PMID: 21232654 PMC: 3026628. DOI: 10.1053/j.seminhematol.2010.11.004.


Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma.

Riccardi A, Mora O, Tinelli C, Valentini D, Brugnatelli S, Spanedda R Br J Cancer. 2001; 82(7):1254-60.

PMID: 10755397 PMC: 2374495. DOI: 10.1054/bjoc.1999.1087.


Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cystostatic policy. Cooperative Group of Study and Treatment of Multiple Myeloma.

Riccardi A, Ucci G, Luoni R, Brugnatelli S, Mora O, Spanedda R Br J Cancer. 1994; 70(6):1203-10.

PMID: 7981078 PMC: 2033710. DOI: 10.1038/bjc.1994.474.


Argyrophilic nucleolar organizer region counts in multiple myeloma: a histopathological study on bone marrow trephine biopsies.

Pich A, Chiusa L, Marmont F, Cappello N, Navone R Virchows Arch A Pathol Anat Histopathol. 1992; 421(2):143-7.

PMID: 1514245 DOI: 10.1007/BF01607047.

References
1.
Fritz E, Ludwig H, Kundi M . Prognostic relevance of cellular morphology in multiple myeloma. Blood. 1984; 63(5):1072-9. View

2.
Valentin-Opran A, Charhon S, Meunier P, Edouard C, Arlot M . Quantitative histology of myeloma-induced bone changes. Br J Haematol. 1982; 52(4):601-10. DOI: 10.1111/j.1365-2141.1982.tb03936.x. View

3.
Stepan J, Neuwirtova R, Pacovsky V, FORMANKOVA J, SILINKOVA-MALKOVA E . Biochemical assessment of bone disease in multiple myeloma. Clin Chim Acta. 1984; 142(2):203-9. DOI: 10.1016/s0009-8981(84)80001-7. View

4.
Greipp P, Raymond N, Kyle R, OFallon W . Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood. 1985; 65(2):305-10. View

5.
Vandermolen L, Rice L, Lynch E . Plasma cell dyscrasia with marrow fibrosis. Clinicopathologic syndrome. Am J Med. 1985; 79(3):297-302. DOI: 10.1016/0002-9343(85)90307-9. View